Literature DB >> 8071596

Use of suicide genes in gene therapy.

P Tiberghien1.   

Abstract

Gene therapy encompasses a broad range of treatment modalities that may eventually be applied to a variety of genetic as well as acquired diseases. In addition to compensating for a defective gene--and enhancing a cellular function--gene transfer can allow for a conditional negative selection of target cells. Indeed, the transfer of a gene encoding a susceptibility factor can make a cell specifically sensitive to a drug. After genomic integration, such as potentially destructive gene is endogenously expressed and has therefore been coined a suicide gene. This review describes current experimental approaches and prospects for using suicide genes for the treatment of human diseases.

Entities:  

Mesh:

Year:  1994        PMID: 8071596     DOI: 10.1002/jlb.56.2.203

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  7 in total

1.  Genetically modified donor leukocyte transfusion and graft-versus-leukemia effect after allogeneic stem cell transplantation.

Authors:  Sylvia Borchers; Elena Provasi; Anna Silvani; Marina Radrizzani; Claudia Benati; Elke Dammann; Annika Krons; Julia Kontsendorn; Joerg Schmidtke; Wolfgang Kuehnau; Nils von Neuhoff; Michael Stadler; Fabio Ciceri; Chiara Bonini; Arnold Ganser; Bernd Hertenstein; Eva M Weissinger
Journal:  Hum Gene Ther       Date:  2011-03-30       Impact factor: 5.695

Review 2.  Gene therapy for mesothelioma.

Authors:  Anil Vachani; Edmund Moon; Steven M Albelda
Journal:  Curr Treat Options Oncol       Date:  2011-06

Review 3.  Current aspects of gene therapy: implications for vascular interventions.

Authors:  F Reifers; J Kreuzer
Journal:  J Mol Med (Berl)       Date:  1995-12       Impact factor: 4.599

Review 4.  Gene therapy in pediatric oncology.

Authors:  E Benaim; B P Sorrentino
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 5.  Gene therapy for lung neoplasms.

Authors:  Anil Vachani; Edmund Moon; Elliot Wakeam; Andrew R Haas; Daniel H Sterman; Steven M Albelda
Journal:  Clin Chest Med       Date:  2011-10-07       Impact factor: 2.878

6.  Long term follow up of patients after allogeneic stem cell transplantation and transfusion of HSV-TK transduced T-cells.

Authors:  Eva M Weissinger; Sylvia Borchers; Anna Silvani; Elena Provasi; Marina Radrizzani; Irene K Beckmann; Claudia Benati; Joerg Schmidtke; Wolfgang Kuehnau; Patrick Schweier; Susanne Luther; Ivonne Fernandez-Munoz; Gernot Beutel; Fabio Ciceri; Chiara Bonini; Arnold Ganser; Bernd Hertenstein; Michael Stadler
Journal:  Front Pharmacol       Date:  2015-04-23       Impact factor: 5.810

Review 7.  Oncolytic Viral Therapy for Mesothelioma.

Authors:  Daniel F Pease; Robert A Kratzke
Journal:  Front Oncol       Date:  2017-08-24       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.